BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koutroubakis IE, Ramos-Rivers C, Regueiro M, Koutroumpakis E, Click B, Schwartz M, Swoger J, Baidoo L, Hashash JG, Barrie A, Dunn MA, Binion DG. The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2015;21:1587-93. [PMID: 25933393 DOI: 10.1097/MIB.0000000000000417] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Petzer V, Theurl I, Weiss G. Established and Emerging Concepts to Treat Imbalances of Iron Homeostasis in Inflammatory Diseases. Pharmaceuticals (Basel) 2018;11:E135. [PMID: 30544952 DOI: 10.3390/ph11040135] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
2 Atkinson MA, Leonard MB, Herskovitz R, Baldassano RN, Denburg MR. Changes in Hepcidin and Hemoglobin After Anti-TNF-alpha Therapy in Children and Adolescents With Crohn Disease. J Pediatr Gastroenterol Nutr 2018;66:90-4. [PMID: 28604512 DOI: 10.1097/MPG.0000000000001650] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 Kim SY, An S, Park DK, Kwon KA, Kim KO, Chung JW, Kim JH, Kim YJ. Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents. Therap Adv Gastroenterol 2020;13:1756284820961302. [PMID: 33029199 DOI: 10.1177/1756284820961302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Shu W, Pang Z, Xu C, Lin J, Li G, Wu W, Sun S, Li J, Li X, Liu Z. Anti-TNF-α Monoclonal Antibody Therapy Improves Anemia through Downregulating Hepatocyte Hepcidin Expression in Inflammatory Bowel Disease. Mediators Inflamm 2019;2019:4038619. [PMID: 31814801 DOI: 10.1155/2019/4038619] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Koutroubakis IE, Ramos-Rivers C, Regueiro M, Koutroumpakis E, Click B, Schoen RE, Hashash JG, Schwartz M, Swoger J, Baidoo L, Barrie A, Dunn MA, Binion DG. Persistent or Recurrent Anemia Is Associated With Severe and Disabling Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2015;13:1760-6. [PMID: 25862987 DOI: 10.1016/j.cgh.2015.03.029] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
6 Koutroumpakis E, Ramos-Rivers C, Regueiro M, Hashash JG, Barrie A, Swoger J, Baidoo L, Schwartz M, Dunn MA, Koutroubakis IE, Binion DG. Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease. Dig Dis Sci 2016;61:865-71. [PMID: 26514677 DOI: 10.1007/s10620-015-3932-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
7 Scarozza P, De Cristofaro E, Scucchi L, Rocchetti I, Marafini I, Neri B, Salvatori S, Biancone L, Calabrese E, Monteleone G. Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases. J Clin Med 2020;9:E2126. [PMID: 32640680 DOI: 10.3390/jcm9072126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Macdougall IC, Comin-Colet J, Breymann C, Spahn DR, Koutroubakis IE. Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency. Adv Ther 2020;37:1960-2002. [PMID: 32297281 DOI: 10.1007/s12325-020-01323-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
9 Lee JL, Yu CS, Lim SB, Park IJ, Yoon YS, Kim CW, Yang SK, Kim JC. Surgical Treatment of Crohn Colitis Involving More Than 2 Colonic Segments: Long-Term Outcomes From a Single Institution. Medicine (Baltimore). 2016;95:e3793. [PMID: 27258512 DOI: 10.1097/md.0000000000003793] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
10 Jung D, Lee S, Jeong I, Oh SH, Kim KM. Short-Term Outcome of Infliximab Therapy in Pediatric Crohn's Disease: A Single-Center Experience. Pediatr Gastroenterol Hepatol Nutr 2017;20:236-43. [PMID: 29302505 DOI: 10.5223/pghn.2017.20.4.236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Lanser L, Fuchs D, Kurz K, Weiss G. Physiology and Inflammation Driven Pathophysiology of Iron Homeostasis-Mechanistic Insights into Anemia of Inflammation and Its Treatment. Nutrients 2021;13:3732. [PMID: 34835988 DOI: 10.3390/nu13113732] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133:40-50. [PMID: 30401705 DOI: 10.1182/blood-2018-06-856500] [Cited by in Crossref: 192] [Cited by in F6Publishing: 183] [Article Influence: 48.0] [Reference Citation Analysis]
13 Núñez-Gómez L, Mesonero-Gismero F, Albillos-Martínez A, López-Sanromán A. Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease. Gastroenterol Hepatol 2018;41:576-82. [PMID: 30054143 DOI: 10.1016/j.gastrohep.2018.06.010] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]